leadf
logo-loader
viewZelira Therapeutics Ltd

Zelira Therapeutics secures $2 million strategic investment and new substantial shareholder

The Thorney Investment Group has increased its existing holding to become a substantial shareholder in Zelira Therapeutics rising to a 5.2% stake.

Zelira Therapeutics Ltd - Zelira Therapeutics secures $2 million strategic investment and new substantial shareholder
Funds will be used to accelerate commercialisation of the company’s portfolio of medicinal cannabis products

Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) has welcomed a $2 million strategic investment from Thorney Investment Group that has resulted in Thorney becoming a substantial shareholder in the company with a 5.2% stake.

Under a private placement to the institutional investor, Zelira will issue 37.037 million new shares at an issue price of 5.4 cents per share, representing a discount of 11.8% of the 15-day volume-weighted average price (VWAP).

Subject to shareholder approval at Zelira’s annual general meeting in November, the company will also issue Thorney a one-for-one free attaching unquoted option, exercisable at 7 cents and expiring two years from the date of issue.

“Accelerating path to commercialisation”

The investment is part of Zelira’s deliberate strategy to increase institutional ownership of the company.

Zelira chairman Osagie Imasogie said: “Zelira is delighted to welcome Thorney Investment Group as a substantial investor in the company.

“With a strong balance sheet and a supportive strategic partner, Zelira is well-positioned to accelerate its path to commercialisation in global markets.”

Funds raised will be used to accelerate the commercialisation of the company’s portfolio of medicinal cannabis products.

“Zelira well-placed”

Thorney Investment Group chairman Alex Waislitz said: “While the global medicinal cannabinoid sector has many entrants, we believe Zelira is well-placed with its life science approach to take advantage of multiple opportunities in multiple jurisdictions.

“The strategic focus on intellectual property protection, together with its capital-light business model we believe positions the company strongly as it commences revenue generation.”

Quick facts: Zelira Therapeutics Ltd

Price: 0.08 AUD

ASX:ZLD
Market: ASX
Market Cap: $94.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics with Proactive at ASX Small and Mid-Cap Conference

Zelira Therapeutics Ltd (ASX:ZLD) managing director Richard Hopkins speaks to Proactive’s Andrew Scott at the virtual ASX Small and Mid-Cap Conference 2020.  The medicinal cannabis company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing...

on 10/9/20

2 min read